This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, X. Articles by Kao, C. Search for Related Content PubMed PubMed Citation Articles by Li, X. Articles by Kao, C.

Departments of ¹ Urology, ² Microbiology and Immunology, ³ Medicine, and ⁴ Pathology, ⁵ Walther Oncology Center, and ⁶ Division of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana

Requests for reprints: Chinghai Kao, Department of Urology, Indiana University School of Medicine. 1001 West 10th Street, Room OPW 320, Indianapolis, IN 46202. Phone: 317-278-6873; Fax: 317-278-3432. E-mail: chkao{at}iupui.edu

Although prostate-restricted replicative adenovirus has exhibited significant antitumor efficacy in preclinical studies, it is necessary to develop more potent adenoviruses for prostate cancer gene therapy. We evaluated the synergistic killing effect of prostate-restricted replicative adenovirus and AdEndoAngio, a replication-defective adenovirus expressing the endostatin-angiostatin fusion protein (EndoAngio). When coadministered with AdEndoAngio, prostate-restricted replicative adenovirus significantly elevated EndoAngio expression, suggesting that AdEndoAngio coreplicates with prostate-restricted replicative adenovirus. Conditioned medium from prostate cancer cells infected by prostate-restricted replicative adenovirus plus AdEndoAngio inhibited the growth, tubular network formation, and migration of human umbilical vein endothelial cells better than conditioned medium from prostate cancer cells infected by AdEndoAngio alone. Furthermore, in vivo animal studies showed that the coadministration of prostate-restricted replicative adenovirus plus AdEndoAngio resulted in the complete regression of seven out of eight treated androgen-independent CWR22rv tumors, with a tumor nodule maintaining a small size for 14 weeks. The residual single tumor exhibited extreme pathologic features together with more endostatin-reactive antibody-labeled tumor cells and fewer CD31-reactive antibody-labeled capillaries than the AdEndoAngio-treated tumors. These results show that combination therapy using prostate-restricted replicative adenovirus together with antiangiogenic therapy has more potent antitumor effects and advantages than single prostate-restricted replicative adenovirus and deserves more extensive investigation. [Mol Cancer Ther 2006;5(3):676–84]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 8/26/05; revised 1/ 3/06; accepted 1/18/06.

This article has been cited by other articles:

				X. Li, Y.-H. Liu, S.-J. Lee, T. A. Gardner, M.-H. Jeng, and C. Kao Prostate-Restricted Replicative Adenovirus Expressing Human Endostatin-Angiostatin Fusion Gene Exhibiting Dramatic Antitumor Efficacy Clin. Cancer Res., January 1, 2008; 14(1): 291 - 299. [Abstract] [Full Text] [PDF]

				X. Li, Y.-H. Liu, Y.-P. Zhang, S. Zhang, X. Pu, T. A. Gardner, M.-H. Jeng, and C. Kao Fas Ligand Delivery by a Prostate-Restricted Replicative Adenovirus Enhances Safety and Antitumor Efficacy Clin. Cancer Res., September 15, 2007; 13(18): 5463 - 5473. [Abstract] [Full Text] [PDF]